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INTRODUCTION
active pharmaceutical ingredients (aPI) with poor aqueous 
solubility are becoming more prevalent in the research and 
development portfolios of discovery focused pharmaceutical 
companies (1). Molecules of this type can encounter a 
number of challenges in pharmaceutical development 
and may subsequently lead to poor dissolution, poor 
systemic availability and consequent poor drug efficacy in 
patients, especially after oral administration. Developments 
in the field of pharmaceutical sciences have led to the 
establishment of a number of approaches for addressing 
the issues of low aqueous solubility. Crystal engineering 
approaches, which can potentially be applied to a wide 
range of crystalline materials, offering substitutive and 
potentially productive and beneficial method for improving 
the solubility, dissolution rate and subsequent bioavailability 
of poorly water soluble compounds for pharmaceutical and 
therapeutic applications (2). The ability to engineer materials 
with optimum dissolution attributes, whilst maintaining 
acceptable physicochemical stability provides a strong driver 
for the utilization of crystal engineering approaches to drug 
and drug intermediate design. The challenges of low aqueous 
solubility provide archetypal situation for the utilization of 
crystal engineering techniques for improving bioavailability, 
whilst also developing pharmaceutically stable, acceptable 
and robust dosage forms. This therefore considers the 
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potential utility of crystal engineering as an approach for 
designing efficacious pharmaceutical dosage forms for poorly 
water soluble drugs. Pharmaceutical cocrystals provides 
an opportunity for the optimization of key physical and 
chemical properties of an aPI whilst retaining its molecular 
structure, and its physiological activity as there are no 
making or breaking of the aPI’s covalent bonds. Significant 
physical, chemical and biological properties of an aPI 
such as its aqueous solubility, bioavailability, stability and 
processability features can be considerably improved upon 
cocrystallization, thus allowing for optimal drug formulation. 
application of the fundamental concepts presented in 
this paper explains to examine the ability of hansen 
solubility parameter to predict the formation of cocrystals 
systems and pharmaceutical properties of cocrystals, in 
particular solubility, dissolution, and stability (3). Several 
research reports of cocrystals show their ability to improve 
physicochemical including solubility, dissolution, stability, 
tabletability and pharmacokinetic characteristics especially 
bioavailability of active pharmaceutical ingredients (4-8). 
Cocrystal synthesis can work as green technique becoming 
avenue for pharmaceutical industry (9).
etodolac, is 2-[(1RS)-1,8-diethyl-1,3,4,9-
tetrahydropyrano[3,4-b]indol-1-yl] acetic acid, (fig.1), is 
a chiral nonsteroidal anti-inflammatory drug. It is used 
as analgesic and anti-inflammatory in the treatment of 
rheumatoid arthritis and osteoarthritis (10). It prohibits 
the synthesis of inflammatory peripheral prostaglandins by 
inhibition of the cycloxygenase-2 enzyme. It produces less 
gastrointestinal toxicity compared to the other nSaIDs (11). 
Its major site of metabolism is liver where it is converted to 
inactive metabolites that are primarily eliminated via the 
renal route (10). 
Figure 1. Chemical structure etodolac 
etodolac was selected as it was associated with poor 
physicochemical characteristics including solubility (12), 
compressibility and flow properties which could be resolved 
with the help of crystal engineering i.e. cocrystallization.
The objective of the present study was to check the 
predictivity of hansen solubility parameter to formation of 
multi-component cocrystals systems of etodolac. This could 
be useful to screen coformers which are having tendency 
to form cocrystals. In the present study we have screened 
various coformers based on predictions from hansen 
solubility parameter prediction. The corystals with maximum 
solubility were selected and evaluated by differntial scanning 
calorimetry, Fourier transform infrared spectroscopy, and 
powder X-ray diffraction.
1.  MATERIALS AND METHODS
2.1  Materials
S-etodolac was provided by IPCa Lab., Mumbai as gift 
sample for study. all other chemicals and solvents used under 
study were of analytical grade and procured from Research 
Fine Lab, Mumbai.
2.2   Methods
2.2.1 Prediction of Co-crystallization by Hansen 
Solubility Parameter (HSP)
Solubility parameters for dry chemical components may be 
obtained by group contribution methods. we have combined 
hoftyzer and Van krevelen method and Fedors group 
contribution method.  In Fedor’s method, the chemical 
structure of etodolac was opened and subsequently the 
chemical structure was considered as open chain structure 
(13-14). The solubility parameter components may be 
calculated from group contributions (F) and molar volume 
(Vm), using the following equations where δd represents 
dispersion forces energy, δp represents polar forces energy 
and δh represents hydrogen bonding energy (15). The 
representative calculations are given in table 1.
δd = (∑Fdi/∑Vm) ------------------eq.(1)
δp =([∑Fpi]0.5/∑Vm) ------------------eq.(2) 
δh = (∑Fhi /∑Vm)0.5------------------eq.(3)
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Table 1. Representative Calculation of hansen Solubility Parameter of etodolac
Group Frequency Fdi(J 1/2cm 3/2mol-1)
Fpi
(J 1/2cm 3/2mol-1)
Fhi
(J/mol)
Vma
(cm3/mol)
–Ch3 2 840 0 0 67
–Ch2– 5 1350 0 0 80.5
–Cooh 1 530 176400 10000 28.5
–nh– 1 160 44100 3100 4.5
phenyl 1 1270 12100 0 52.4
>Ch– 2 160 0 0 -2.0
–o– 1 100 160000 3000 3.8
>C< 1 380 0 0 32
Ring closure 2 0 0 0 -4.4
Conjugation in 
ring
2 -70 0 0 -19.2
∑ 4720 392600 16100 243.1
The resultant ∆δ values of etodolac and selected coformers (table 2) were compared to predict their solid state miscibility (16).
Table 2. Theoretical prediction of cocrystal formation by Van kreevalen’s method based on miscibility predictions.
Compound δd δp δh δt Δδt REMARK 
etodolac 19.41 2.577 8.13 21.2 --- -----
Salicylic acid 20.1 6.22 15.4 26.07 4.87 MISCIBLe 
Benzoic acid 19.62 4.35 10.01 22.45 1.25 MISCIBLe 
Malonic acid 18.19 8.13 16.54 25.89 4.69 MISCIBLe 
Cinnamic acid 18.6 3.42 8.88 20.89 0.31 MISCIBLe 
L-tartaric ecid 20.25 11.4 27.22 35.79 14.59 IMMISCIBLe 
p-Aminobenzoic acid 20.78 4.34 13.56 25.19 3.99 MISCIBLe 
Hippuric acid 20.41 6.92 10.72 24.07 2.87 MISCIBLe 
Ferulic acid  18.37 4.92 14.56 23.95 2.75 MISCIBLe 
Maleic acid 17.38 7.07 15.43 24.29 3.09 MISCIBLe 
Glutaric acid 17.76 5.64 13.78 23.17 1.92 MISCIBLe
Urea 17.28 15.65 19.55 30.42 9.22 IMMISCIBLe
Ascorbic acid 27 5.64 13.78 23.17 1.97 MISCIBLe
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2.2.1  Preparation of cocrystals
etodolac was cocrystallized with various cocrystals formers 
(CCF) in the 1:1 Mol stoichiometric ratio using agate 
mortar and pestle by neat grinding method. The grinding 
was performed for 20 minutes for each batch (17). The flow 
properties of cocrystals were determined from angle of 
repose, hausner’s ratio and Carr’s Index.
2.2.2 Melting point determination
The melting point of etodolac, CCFs and cocrystals were 
determined by Digital melting point apparatus (LaB-
tRonICS Ltd) in triplicate.
2.2.3  Differential Scanning Calorimetry (DSC)
Thermal analysis of etodolac and cocrystals was performed by 
using a differential scanning calorimeter DSC-60a Shimadzu 
calorimeter. The samples were  placed  in  aluminum  pans, 
sealed  hermetically  and  then  these hermetically sealed 
aluminum pans were heated at a scanning rate of 20°C/min 
from 50° to 350°C under constant purging dry nitrogen flow 
(20mL/min). empty aluminum pan was used as a reference.
2.2.4  Fourier Transfer-Infrared Spectroscopy (FTIR)
Shimadzu FtIR spectrometer Prestige 21 with DRS assembly 
was used in attenuated total reflectance (atR) mode for 
collecting Ft-IR spectra of samples.  The spectrums were 
collected over the range of 4000-400cm-1 in 45 scans, with a 
resolution of 5 cm-1 for each sample.
2.2.5 Powder X-Ray diffraction Study (PXRD)
In this study, a powder sample of etodolac and cocrystals was 
exposed to a beam of monochromatic X-ray radiation using 
a Bruker D8 Discover, which was diffracted and recorded by 
an X-ray detector. The diffracted data was processed and an 
X-ray diffraction pattern of powder was plotted.
2.2.6  Solubility Study 
Saturation solubility studies etodolac and its cocrystals were 
performed in according to method reported by higuchi and 
Connors (18). For saturation solubility, an excess quantity 
of cocrystals was added to vials containing 10ml of different 
solvent media. The vials were then subjected to rotary shaking 
for 24 hours. after shaking the solutions were filtered through 
whatman filter paper no.41 and the filtrate was analyzed by 
UV spectrophotometer (SICan 2310, Inkarp Instruments) 
at 280 nm with appropriate dilutions. 
2.2.7    Preparation of Immediate release tablets of etodolac 
Cocrystals
Immediate release tablet formulation of etodolac cocrystals 
was prepared by wet granulation method by 22 factorial 
experimental design. The disintegrant cross-carmellose 
sodium and binder poly vinyl pyrrolidone k30 (PVP-k30) 
were selected as independent variable. The formulae were as 
given in table 3.
Table 3. Formulae for experimental factorial batches
Ingredients Quantity
etodolac: Salicylic acid cocrystals 435 mg
Cross carmellose sodium 5%-7%
PVP k30 2.5%-5%
MCC Ph-101 q.s
Magnesium stearate 1%
total weight 520mg
2.2.8 Dissolution study of cocrystals and its formulation
In vitro dissolution study was carried out using a USP type 
2 apparatus (USP tablet Dissolution apparatus Veego VDa-
6DR) at a rotation speed of 100 rpm. Dissolution medium 
selected was phosphate buffer ph 6.8 (volume 1000ml, 
temperature 37ºC). after each sampling intervals, sample 
withdrawn was replaced by same amount of dissolution 
media kept at same temperature. The  sample  withdrawn 
was  then  immediately  filtered  and  analyzed  for  sample 
content by UV  spectrophotometer  at 280 nm after suitable 
dilutions.
2.2.9 Stability Study
The immediate release tablets of etodolac-salicylic acid 
cocrystals were packed in aluminum foil and stored under 
the following  environmental  conditions  for  a period  of 
one  month  as prescribed  by  ICh conditions at 5°C ± 30°C 
and 25° ± 2°C/ Rh 60% ± 5%. The tablets were withdrawn 
at end of 15th and 30th day and evaluated for parameters 
including color change, assay (drug content), disintegration 
time, and dissolution study of formulation.
2. RESULTS AND DISCUSSION
The melting point of etodolac (etd) and cocrystals were as 
reported in table 4. It was observed that the melting point 
lower than the individual aPI or CCF indicating interaction 
between them. The Solubility of etodolac was significantly 
improved by cocrystal formation with salicylic acid, para 
amino benzoic acid and fumaric acid as compared other CCF 
under study. 
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Table 4. Melting Point, Solubility of cocrystals prepared by neat Grinding
Batch
Code Drug/Coformer M.P of coformer (
0C) M.P. of cocrystal (by digital melting apparatus)(0C) Solubility(mg/L)
F1 etoDoLaC (etd) 145-148 ---- 676±3.0
nF1 etd Salicylic acid 157-159 116-118 1566±5.33
nF2 etd Benzoic acid 122 104-107 155±2
nF3 etd Malonic acid 134-136 117-118 49.2±3.26
nF4 etd Cinnamic acid 132-134 112-116 233±2.66
nF5 etd tartaric acid 204-206 202-206 215±2.55
nF6 etd p-aBa 185-188 117-121 3266±1.79
nF7 etd hippuric acid 187-190 131-136 204.9±2.90
nF8 etd Ferulic acid 174 125-133 2186±4.33
nF9 etd Maleic acid 138-139 90-11 174.1±2.56
nF10 etd Glutaric acid 94-97 117-118 134.1±4.56
nF11 etd Urea 133 sticky in nature -
nF12 etd ascorbic acid 95-98 sticky in nature  - 
The flow properties of etodolac and its cocrystals were 
as represented in table 5. It reveals that there was marked 
improvement in flow properties of etodolac in cocrystals 
with salicylic acid as compared to the cocrystals with PaBa 
and ferulic acid. 
Table 5. Flow properties of etodolac and its cocrystals
Parameters/Batch Etodolac NF1 NF6 NF8
Bulk density         
(gm/cm3) 0.315 0.311 0.222 0.323
tapped density     
(gm/cm3) 0.485 0.401 0.321 0.474
Compressibility 
index (%) 35.05 22.40 30.84 31.85
hausner’s ratio 1.53 1.28 1.44 1.46
angle of repose (°) 36.33 17.43 33.66 28.59
The melting points of etodolac, nF1-cocrystal, n6-cocrystal and 
nF8-cocrystal were determined by DSC study and found to be 
153.74°C, 119.44°C, 125.44°C, 127.28°C respectively (Fig.2 and 
3).  From the  results  of  DSC  study,  the  cocrystals  formation 
(i.e. nF1, nF6, nF8 cocrystals)  can  be  confirmed  which show 
characteristic change in the melting behavior. Such peculiar 
change in melting behaviour confirms the formation of new 
phase suggesting cocrystal formation. In DSC thermograms 
the distinct endothermic peaks at temperature other than 
the melting peak of drug and CCFs and change in heat were 
observed indicating formation of cocrystal.
The FtIR spectra of aPI and cocrystals are shown in fig 2 
and 4. the carbonyl peak in the region 1680-1760cm−1, 
-nh stretching region between 3300-3500 cm−1, ether 
(-o-) peak in the region between 1000 and 1300cm−1 of 
etodolac was retained in  all  cocrystals spectrums. In most 
of the cocrystals, distinctive peaks for hydrogen bonding 
conformation were observed in Ft-IR spectrum. the 
hydrogen bonding in cocrystals by Ft-IR spectroscopy is 
detected by observing a decrease in intensity of C - o-C 
peak and appearance of low frequency broad C - o-C 
band. Broad features were observed in the region of 900-
1500cm−1, indicating the occurrence of hydrogen bonding. 
a decrease in n-h stretching frequency indicates that 
hydrogen is participating in hydrogen bonding.  The  extent 
of  hydrogen  bonding  can  be  determined  by  extent  of 
decrease in  frequency  and relative band broadening.  The 
lowering of frequency is the function of degree and strength 
of hydrogen bonding. The significant changes observed in 
the region of amine (n-h) and carbonyl(C=o) stretching 
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indicated formation of new hydrogen bonds.
The crystal structure of the etodolac and cocrystals (nF1, 
nF6, nF8) was confirmed by X-ray powder diffraction 
analysis (fig.2 and 5). The comparison of PXRD pattern 
of etodolac with its cocrystals reveals that there may be 
formation cocrystal as additional intense peaks were 
observed in cocrystals. It suggests development of new 
crystalline phases in cocrystals.
In a saturated solubility study of etodolac cocrystals it was 
observed that maximum improvement in solubility was 
observed with CCF in following order p-aminobenzoic 
acid>ferulic acid> salicylic acid (table 4). It may be attributed 
to desirable noncovalent interaction between and aPI 
and CCF. Cocrystal with PaBa shown discoloration with 
time while cocrystals with ferulic acid shown overlapping 
absorption in ultraviolet region with etodolac. Glutaric 
acid, urea and L-ascorbic acid formed undesirable sticky 
semisolid material during cocrystallization attempts with 
etodolac. while with other coformers under study solubility 
of etodolac was decreased.
Figure 2. Thermal and spectroscopic study a) DSC thermogram of etodolac B) FtIR spectra of etodolac C) XRD diffractogram 
of etodolac
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Figure 3. Thermal study (DSC Thermogram ) of cocrystals a)nF1 B)nF6 C) nF8
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Figure 4. Spectroscopic study (FtIR Spectra) of cocrystal a) nF1 B) nF6 C) nF8
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Figure 5.  XRD study (diffractogram) of cocrystals a) nF1 B) nF6 C) nF8
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Figure 6. Powder dissolution study of aPI and cocrystals in 
dist. water
Figure 7. Dissolution study in phosphate buffer ph 6.8
The results of powder dissolution study as shown in 
fig.6 reveal that dissolution of etodolac was improved 
by co-crystallization with salicylic acid, ferulic acid and 
p-aminobenzoic acid. The dissolution of the wet granulation 
immediate release tablet batches F1 to F4 and marketed tablet 
showed that almost overlapping dissolution profile (Fig. 
7). The Batch -F3 batch was selected as optimized batch as 
comparatively highest dissolution was obtained as compared 
to other immediate release tablet batches and found that it 
was stable under stability study.
3. CONCLUSION
Calculations of hansen solubility parameters were employed 
for theoretical predictions of cocrystals of etodolac based 
on miscibility of aPI and cocrystal former. It shows limited 
scope for prediction of cocrystal formation. The neat 
grinding method of edotolac cocrystal synthesis resulted 
in improvement of solubility with PaBa, ferulic acid and 
salicylic acid when they are used as cocrystal formers. It 
can serve as green method for improving physicochemical 
characteristics of etodolac.
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Etodolak’ın Ko-kristalizasyonu: Ko-kristalizasyon Tahmini, 
Ko-kristal Sentezi, Katı Faz Yapı Aydınlatma Çalışmaları ve 
In Vitro İlaç Salımı
ÖZ
Bu araştırma kapsamında, etodolak ko-kristallerinin sentezi 
ve farklı koformerlerin yapılarının aydınlatılması ile hansen 
çözünürlük paratmetrelerinin tayini çalışılmıştır. etodolak’ın 
çözünürlüğünün arttırılması ve dissolüsyon özelliğinin 
iyileştirilmesi amacıyla hazırlanan etodolak ko-kristallerinin 
farklı koformerleri izlenmiştir. ko-kristallerin yapısı;  Fourier 
dönüşümlü infrared spektroskopisi (FtIR), diferansiyal 
taramalı kalorimetri (DSC) tayini, X-ışını kırınım (PXRD) 
tayini ile aydınlatılmış, ayrıca çözünürlük ve çözelti doygunluğu 
çalışmaları, in vitro dissolüsyon ve stabilite çalışmaları 
yapılmıştır. Çalışma sonucunda etodolak’ın, p-amino benzoik 
asit, ferrulik asit ve salisilik asit ile kokristalleri hazırlandığında 
çözünürlüğünün arttığı tespit edilmiştir. etodolak:Salisilik 
ait 1:1M kokristalinin hızlı ilaç salımı için formüle edilen 
tablet içeriğinde kullanılması öngörülmüştür. etodolak ko-
kristallerinin yeterli farmasötik stabiliteye sahip oldukları ve 
etodolak’ın çözünürlük ve dissolüsyon özelliğini arttırdıkları 
sonucuna ulaşılmıştır.
Anahtar kelimeler: etodolak, ko-kristal, Çözünürlük, 
Dissolüsyon, hansen Çözünürlük Parametresi
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